Figure 6

Effects of MAP kinases and the NF-κB inhibitors on resveratrol-mediated inhibition of p35 promoter activity. A) Stable clone C7 PC12 cells were untreated (control), treated with resveratrol (25 μM), MEK inhibitor U0126 (20 μM), and resveratrol (25 μM) plus U0126 (20 μM) during 24 h and luciferase activity was measured. Co-treatment of resveratrol plus U0126 had a further inhibitory effect over p35 promoter activity. On the other hand, B) p38 MAP kinase inhibitor (SB203580 20 μM), C) JNK inhibitor (SP600125 20 μM) and D) NF-κB inhibitor (1 μM), all of them significantly increased p35 promoter activity in cells treated with resveratrol (25 μM). All data are presented as the mean and SEM (n = 4). a, b p < 0.05 (t-test). a mean control values compared with different treatments. b mean resveratrol values compared with resveratrol plus corresponding inhibitor.